Data on Terlivaz for injection in adult patients with hepatorenal syndrome to be presented at the National Kidney Foundation (NKF) 2023 Spring Clinical Meeting (SCM)

Terlivaz is the first and only FDA-approved product indicated to improve kidney function in adults with hepatorenal syndrome (HRS) with rapid reduction in kidney function,an acute and life-threatening condition requiring hospitalization.

The findings from one of the abstracts, presented by Xingyue Huang, PhD, Senior Director, HEOR, Critical Care at Mallinckrodt, provide insight into the treatment cost per response in patients with hepatorenal syndrome treated with Terlivaz plus albumin versus other unapproved treatments from a U.S. hospital perspective. Furthermore, findings from a pooled analysis of three Phase III terlipressin trials, presented by Muhammad A Mujtaba, MD, University of Texas Medical Branch, Galveston TX, offer perspective into the clinical impact of serum creatinine reduction from treatment initiation with Terlivaz through end of treatment on outcomes for adults with hepatorenal syndrome.

See- Poster #10: "Treatment-Related Cost Analysis for Adults with Hepatorenal Syndrome with Rapid Reduction in Kidney Function"- Presenter: Xingyue Huang, PhD, Senior Director, HEOR, Critical Care at Mallinckrodt Presentation Date: Wednesday, April 12, 2023; 6:00 – 7:30PM CDT.

See-Poster #20: "A Reduction in Serum Creatinine of at Least 30% Leads to Meaningful Clinical Outcomes in Patients with Hepatorenal Syndrome Type 1: A Pooled Analysis of 3 Phase III Studies. Presenter: Muhammad Ahmad Mujtaba, MD, University of Texas Medical Branch Presentation Date: Wednesday, April 12, 2023; 6:00 – 7:30PM CDT.